Development, fabrication and evaluation of transdermal drug delivery system - A review

Pharmaceutical Reviews

Volumn 7, Issue 5, 2009, Pages

  Aggarwal, Geeta ^a   Dhawan, Sanju ^b  

^a Rayat Institute of Pharmacy   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Design of transdermal patches; Evaluation of transdermal system; Permeation enhancers; Transdermal drug delivery system

Indexed keywords

CLONIDINE; COPOLYMER; ELASTOMER; ESTRADIOL; GLYCERYL TRINITRATE; NICOTINE; SCOPOLAMINE;

DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG RELEASE; DRUG SCREENING; REVIEW; TRANSDERMAL PATCH;

EID: 77953443568     PISSN: None     EISSN: 19185561     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. Kandavilli S, Nair V, Panchagnula R. Polymers in transdermal drug delivery systems, Pharmaceutical Technology 2002, 62-78. Available from: www.pharmtech.com. Accessed on 15 Jan,2008.
2. Guy RH. Current status and future prospects of transdermal drug delivery, Pharm Res 1996, 13, 1765-1769.
3. Guy RH, Hadgraft J, Bucks DA. Transdermal drug delivery and cutaneous metabolism, Xenobiotica 1987, 7, 325-343.
4. Chein YW. Transdermal Controlled Systemic Medication. New York and Basel, Marcel Dekker Inc. 1987; 159 - 176.
5. Keith AD. Polymer matrix considerations for transdermal devices, Drug Dev. Ind. Pharm 1983, 9, 605.
6. Baker RW, Heller J. Material selection for transdermal delivery systems; In: Hadgraft J, Guys RH, editors. Transdermal Drug Delivery: Development Issues and Research Initiatives. New York, Marcel Dekker Inc. 1989; 293-311.
7. Guyot M, Fawaz F. Design and in vitro evaluation of adhesive matrix for transdermal delivery of propranolol, Int J Pharm 2000, 204, 171-182.
8. Gabiga H, Cal K, Janicki S. Effect of penetration enhancers on isosorbide dinitrate penetration through rat skin from a transdermal therapeutic system, Int J Pharm 2000, 199, 1-6.
9. Minghetti P, Cilurzo F, Casiragh A, Molla FA, Montanari L. Dermal patches for controlled release of miconazole: Influence of drug concentration on the technical characteristics, Drug Dev Ind Pharm 1999, 25, 679-684.
10. Tsai CJ, Hu LR, Fang JY, Lin HH. Chitosan hydrogel as a base for transdermal delivery of berberine and its evaluation in rat skin, Biol. Pharm. Bull 1999, 22, 397-401.
11. Bromberg L. Cross linked polyethylene glycol networks as reservoirs for protein delivery, J Apply Poly Sci 1996, 59, 459-466.
12. Verma PRP, Iyer SS. Transdermal delivery of propranolol using mixed grades of eudragit: Design and in vitro and in vivo evaluation, Drug Dev Ind Pharm 2000, 26, 471-476.
13. Ubaidulla U, Reddy MV, Ruckmani K, Ahmad FJ, Khar RK. Transdermal therapeutic system of carvedilol: Effect of hydrophilic and hydrophobic matrix on in vitro and in vivo characteristics, AAPS PharmSciTech 2007, 8(1), Article 2.
14. Gannu R, Vamshi Vishnu Y, Kishan V, Madhusudan Rao Y. Development of nitrendipine transdermal patches: In vitro and ex vivo characterization, Current Drug Delivery 2007, 4, 69-76.
15. Gale R, Spitze LA. Permeability of camphor in ethylene vinyl acetate copolymers. In proceedings: Eighth International Symposium on Controlled Release of Bioactive Materials. Minneapolis, MN, Controlled Release Society. 1981; 183.
16. Boretos JW, Detmer DE , Donachy JH. Segmented polyurethane: a polyether polymer II. Two year experience, J Biomed Mat Res 1971, 5, 373.
17. Chung SJ. Future drug delivery research in South Korea, J Controlled Release 1999, 62, 73-79.
18. Izumoto T, Aioi A, Uenoyana S, Kariyama K, Azuma M. Relationship between the transference of drug from a transdermal patch and physicochemical properties, Chem Pharm Bull (Tokyo) 1992, 40, 456-458.
19. Gordon RA, Peterson TA. Four myths about transdermal drug delivery, Drug Delivery Technology 2003, 3, 1-7.
20. Williams AC, Barry BW. Penetration enhancers, Advanced drug delivery reviews 2004, 56, 603-618.
21. Karande P, Jain A, Ergun K, Kispersky V, Mitragotri S. Design principles of chemical penetration enhancers for transdermal drug delivery, Proceedings of the national academy of sciences of the United States of America 2005,102, 4688-4693.
22. Thornfeldt CR. Potent penetration enhancers. US Patent 5760096 (1998).
23. Ning YM, Rao YF, Liang WQ. Influence of permeation enhancers on transdermal delivery of anemonia, Zhonqquo Zhong Yao Za Zhi 2007, 32, 393-396.
24. Budhathoki U, Thapa P. Effect of chemical enhancers on in vitro release of salbutamol sulfate from transdermal patches, Kathmandu University of Science Engineering and Technology 2005, 1(1), 1-8.
25. Zurdo SI, Franke P, Schaefer UF, Lehr CM. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs, J. Controlled Release 2007, 118, 196-203.
26. Babu RJ, Pandit JK. Effect of permeation enhancers on the transdermal delivery of bupranolol through rat skin, Drug Delivery 2005, 12, 165-169.
27. Oquiso T, Iwaki M, Paku T. Effect of various enhancers on transdermal penetration of indomethacin and urea and relationship between penetration parameters and enhancement factors, J Pharm Sci 1995, 84, 482-488.
28. Parikh DK, Tapash KG. Feasibility of transdermal delivery of fluoxetine, AAPS PharmSciTech. 2005, 6, E144-149.
29. Nokodchi A, Shokri J, Dashbolaghi A, Hassan Zadeh D, Ghafourian T, Barzegar Jalali M. The enhancement effect of surfactants on the penetration of lorazepam through rat skin, Int J Pharm 2003, 250, 359-369.
30. Mukherjee B, Kanupriya, Mahapatra S, Das S, Patra B. Sorbitan monolaurate 20 as a potential skin permeation enhancer in transdermal patches, J Applied Research 2005, 5, 96-107.
31. El-Kattan AF, Asbill CS, Kim N, Mickniak BB. Effect of formulation variables on the percutaneous permeation of ketoprofen from gel formulations, Drug Delivery 2000, 7, 147-153.
32. Huang YB, Fang JY, Hung CH, Wu PC, Tsai YH. Cyclic monoterpine extract from cardamom oil as a skin permeation enhancer for indomethacin: in vitro and in vivo studies, Biol Pharm Bull 1999, 22, 642-646.
33. Kaza R, Pitchaimani R. Formulation of transdermal drug delivery system: Matrix and selection of polymer- their evaluation, Current Drug Discovery Technologies 2006, 3, 279-285.
34. Giannakou SA, Dellas PP, Kekkas PM, Choulis NH. Development and in vitro evaluation of nimodipine transdermal formulations using factorial design, Pharm Dev Technol 1998, 3, 517-525.
35. Jayaaraam B, Bhaskar P. Formulation of an HPMC gel drug reservoir system with ethanol water as a solvent system and limonene as a permeation enhancer for enhancing in vitro transdermal delivery of nicorandil, J Pharmacological and Biophysiological Research 2004,17, 310-320.
36. Shin SC, Shin EY, Cho CY. Enhancing effects of fatty acids on piroxicam permeation through rat skins, Drug Dev Ind Pharm 2000, 26, 563-566.
37. Pocius AV. Adhesives. In: Howe- Grants M, Ed. Kirk-Othmer Encyclopedia of Chemical Technology. New York, Wiley-Interscience. 1991; 445-466.
38. Walters KA. Transdermal drug delivery systems In: Swarbick K, Boylan JC, eds. Encyclopedia of pharmaceutical technology. New York, Marcel Dekker Inc. 1997; 253-293.
39. Franz TJ. Transdermal Delivery. In: Kydonieus A, ed. Treatise on controlled drug delivery: Fundamentals, optimization, applications. New York, Marcel Dekker Inc. 1991; 341-421.
40. Tan HS, Pfister WR. Pressure sensitive adhesives for transdermal drug delivery, Pharm Sci Technol Today 1999, 2, 60-69.
41. Pfister WR, Hsieh DS. Permeation enhancers compatible with transdermal drug delivery systems. Part I: Selection and formulation considerations, Med Device Technol 1990, 1, 48-55.
42. Godbey KJ. Improving patient comfort with nonocclusive transdermal backings, American Association of Pharmaceutical Scientists 1996, 1-2.
43. Foco A, Hadziabdic J, Becic F. Transdermal drug delivery systems, Med Arch 2004, 58, 230-234.
44. Khatun M, Ashraful Islam SM, Akter P, Abdul Quadir M, Selim Reza M. Controlled release of naproxen sodium from eudragit RS 100 transdermal film, Dhaka University J Pharm Sci 2004, 3(1-2).
45. Rao PR, Diwan PY. Permeability studies of cellulose acetate free films for transdermal use: Influence of plasticizers, Pharm Acta Helv 1997, 72, 47-51.
46. Gondaliya D, Pundarikakshudu K. Studies in formulation and pharmacotechnical evaluation of controlled release transdermal delivery system of bupropion, AAPS PharmSciTech 2003, 4, Article3.
47. Davis SS. Delivery system for biopharmaceuticals, J Pharm Pharmacol 1992, 44, 186-190.
48. Costa P, Ferreria DC , Morgado R, Sousa Lobo JM. Design and evaluation of a lorazepam transdermal delivery system, Drug Dev Ind Pharm 1997, 23, 939-944.
49. Mutalik S, Udupa N. Formulation development, in vitro and in vivo evaluation of membrane controlled transdermal systems of glibenclamide, J Pharm Pharmaceut Sci 2005, 8, 26-38.
50. Misra AN. Transdermal Drug Delivery. In: Jain NK, ed. Controlled and novel Drug Delivery. New Delhi , Varghese Publication. 1997.
51. Murthy NS, Hiremath SR. Formulation and evaluation of controlled release transdermal patches of theophylline-salbutamol sulfate, The Internet J Pulmonary Medicine 2001, 1(1), 1-7.
52. Mutalik S, Udupa N. Glibenclamide transdermal patches: Physicochemical, pharmacodynamic and pharmacokinetic evaluations, J Pharm Sci 2004, 93, 1577-1594.
53. Samanta MK, Dube R, Suresh B. Transdermal drug delivery system of haloperidol to overcome self induced extrapyramidal syndrome, Drug Dev Ind Pharm 2003, 29, 405-415.
54. Chien YW. Logics of transdermal controlled drug administration, Drug Dev Ind Pharm 1983, 9, 497.
55. Lewis S, Pandey S, Udupa N. Design and evaluation of matrix type and membrane controlled transdermal delivery systems of nicotine suitable for use in smoking cessation, Ind J Pharm Sci 2006, 68, 179-184.
56. Liang BW, Chang YP, Lu Y. Study of EVA membrane controlled release patch of scopolamine, Chinese Pharm J 1990, 25, 209-211.
57. Krishna R, Pandit JK. Transdermal delivery of propranolol, Drug Dev Ind Pharm 1994, 20, 24-59.
58. Baker RW. Development of an estriol releasing intrauterine device, J Pharm Sci 1979, 68, 20-26.
59. Arabi H, Hashemi SA, Ajdari N. Preparation of a transdermal delivery system and effect of membrane type for scopolamine drug, Iranian Polymer J 2002, 11(4), 245-249.
60. David RS. Transdermal systems for overactive bladder: Principles and Practice, Rev Urol 2003, 5, S26-S30.
61. Chien YW, Tojo K. Transdermal verapamil delivery device. US Patent 4690683 (1983).
62. Walter M. Transdermal therapeutic system (TTS) with fentanyl as active ingredient. European Patent EP 1418951 (2004).
63. Venkateshwaran S, Fikstad D, Ebert CD. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents. US Patent 5985317 (1999).
64. Rachel JB, Richard JC, Chris PT, Charles MH. In vitro transdermal delivery of major catechins and caffeine from extract of Camellia sinensis, Int J Pharm 2004, 28, 45-51.
65. Kanikkannan N, Andega S, Burton S, Babu RJ, Singh M. Formulation and in vitro evaluation of transdermal patches of melatonin, Drug Dev Ind Pharm 2004, 30, 205-212.
66. Lake Y, Pinnock S. Improved patient acceptability with a transdermal drug in adhesive oestradiol patch, J Obstet Gynecol 2000, 40, 313-316.
67. Aquil M, Ali A, Sultana Y, Najmi AK. Fabrication and evaluation of polymeric films for transdermal delivery of pinacidil, Pharmazie 2004, 59, 631-635.
68. Bagyalakshmi J, Vamsikrishna RP, Manavalan R, Ravi TK, Manna PK. Formulation development and in vitro and in vivo evaluation of membrane moderated transdermal systems of ampicilline sodium in ethanol: pH 4.7 buffer solvent system AAPS PharmSciTec. 2007, 8, Article 7.
69. Baichwal MR. Polymer films as drug delivery systems. In: Advances in drug delivery systems. Bombay , MSR Foundation. 1985; 136-147.
70. Khan TA, Peh KK, Chung HS. Mechanical, bioadhesive strength and biological evaluation of chitosan films for wound dressing, J Pharm Pharmceut Sci 2000, 3, 303-311.
71. Zupan JA. Use of eucalyptol for enhancing skin permeation of bioaffecting agents. Eur. Patent 0069385 (1982).
72. Mundargi RC, Patil SA, Agnihotri SA, Aminabhavi TM. Evaluation and controlled release characteristics of modified xanthan films for transdermal delivery of atenolol, Drug Dev Ind Pharm 2007, 33, 79-90.
73. Minghetti P, Cilurzo F, Casiraghi A. Measuring adhesive performance in transdermal delivery systems, Am J Drug Deliv 2004, 2, 193-206.
74. Minghetti P, Cilurzo F, Tosi L, Casiraghi A, Montanari L. Design of a new water soluble pressure sensitive adhesive for patch preparation, AAPS PharmSciTech 2003, 4, Article 8.
75. ASTM. Standard test method for pressure-sensitive adhesive using an inverted probe machine. American Society for testing and materials, Philadelphia, USA . 1971, 2979-3071.
76. th ed., Pressure sensitive adhesive tape council, Glenview, IL. 1976.
77. Ho KY, Dodou K. Rheological studies on pressure sensitive adhesives and drug in adhesive layers as a means to characterize adhesive performance, Int J Pharm 2007, 333, 24-33.
78. Dimas DA, Dalles PP, Rekkas DD, Choulis NH. Effect of several factors on the mechanical properties of pressure sensitive adhesives used in transdermal therapeutic systems, AAPS PharmSciTech 2000, 1, E16.
79. Sood A, Panchagnula R. Role of dissolution studies in controlled release drug delivery system, STP Pharma Sci 1999, 9, 157-168.
80. Higuchi T. Mechanism of sustained action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices, J Pharm Sci 1963, 52, 1145-1149.
81. Desai SJ, Singh P, Simonellir AP, Higuchi WI. Investigation of factors influencing release of solid drug dispersed in wax matrices. III. Quantitative studies involving polyethylene plastic matrix, J Pharm Sci 1966, 55, 1230-1234.
82. Ritschel WA. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release per oral drug delivery systems, Drug Dev Ind Pharm 1989, 15, 1073-1103.
83. Ritger PL, Peppas NA. A simple equation for description of solute release.1. Fickian and Non - Fickian release from non swellable devices in the form of slabs, spheres, cylinder or discs, J Control Release 1987, 5, 23-36.
84. Tymes NW, Shah VP, Skelly JP. In vitro release profile of estradiol transdermal therapeutic systems, J Pharm Sci 2006, 79, 601-602.
85. Siewert M, Dressman J, Brown CK, Shah VP. FIP/AAPS guidelines to dissolution / in vitro release testing of novel / special dosage forms, AAPS PharmSciTech. 2003, 4, Article 7.
86. Murthy SN, Hiremath SRR. Physical and chemical permeation enhancers in transdermal delivery of terbutaline sulfate, AAPS Pharm SciTech 2001, 2, Article1.
87. Elias PM. Lipids and the epidermal permeability barrier, Arch Dermatol 1981, 270, 95-117.
88. Scott RC, Walker M, Dugard PH. In vitro percutaneous absorption experiments. A technique for production of intact epidermal membrane from rat skin, J Soc Cosmet Chem 1986, 37, 35-41.
89. Jain NK, Thomas NS, Panchagnula R. Transdermal drug delivery of imipramine hydrochloride I Effect of terpenes, J Control Release 2002, 79, 93-101.
90. Walker M, Dugard PH, Scott RC. In vitro percutaneous absorption studies: a comparison of human and laboratory species, Hum Toxicol 1983, 2, 561-562.
91. Jeferey JB, James JL. Transcutaneous drug delivery: A practical review, Mayo Clin Proc 1995, 70, 581-586.
92. Wester RC, Maibach HI. Percutaneous absorption in the rhesus monkey compared to man, Toxicol Appl Pharmacol 1975, 32, 394-398.
93. Wester RC, Maibach HI. Percutaneous absorption: Neonate compared with adult. In: Hunt MKD., ed. Environmental factors in human growth and development. Cold Spring Harbor, New York, Cold Spring Harbor Press 1982, 3-15.
94. Panchagnula R, Bokalial R, Sharma P, Khandavilli S. Transdermal delivery of naloxone: skin permeation, pharmacokinetic, irritancy and stability studies, Int J Pharm 2005, 293, 213-223.